Novartis | Resultat Før Skatt



Pre Tax Profit Endring Dato
AbbVie USD 4.81B 1.54B 2024-12
Alcon AG USD 349M 112M 2024-12
Almirall EUR 15.17M 72K 2024-06
Amgen USD 3.38B 111M 2024-12
AstraZeneca USD 1.67B 162M 2024-12
Autolus Therapeutics Ltd -82070000 23.85M 2024-09
Bayer EUR -481000000 805M 2024-12
Biogen USD 572.2M 118.5M 2024-12
Bristol-Myers Squibb USD 4.26B 226M 2024-12
Eli Lilly USD 5.54B 3.83B 2024-12
Fresenius EUR 401M 14M 2024-12
Fresenius Medical Care EUR 179.93M 201.07M 2024-12
Galapagos EUR 19.03M 68.17M 2024-12
Genmab DKK 3.6B 1.88B 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
GlaxoSmithKline GBP 563M 2.08B 2024-12
GRIFOLS EUR 66.98M 38.41M 2024-06
Hikma Pharmaceutical USD 144M 144M 2024-06
J&J USD 5.42B 1.86B 2024-12
Lonza CHF 427M 167M 2024-06
Merck EUR 1.23B 449.38M 2024-09
Merck USD 5.22B 114M 2024-12
Novartis USD 4.66B 269M 2024-12
Novartis USD 4.66B 269M 2024-12
Novo Nordisk 34.38B 9.05B 2024-09
Orion EUR 91.7M 109.7M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Philips EUR 246M 411M 2024-09
Recordati EUR 150.03M 19.43M 2024-09
Regeneron Pharmaceuticals USD 958.1M 534.9M 2024-12
Roche Holding CHF 1.78B 2.33B 2024-12
Sanofi EUR 2.18B 1.33B 2024-12
UCB EUR 123M 464.07M 2024-06



Novartis Resultat Før Skatt - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.